106 results on '"Pfoehler, Claudia"'
Search Results
2. Early versus late response to PD-1-based immunotherapy in metastatic melanoma
3. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
4. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
5. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
6. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG
7. Fatal and Near-Fatal Anaphylaxis: Data From the European Anaphylaxis Registry and National Health Statistics
8. Age- and Elicitor-Dependent Characterization of Hymenoptera Venom-Induced Anaphylaxis in Children and Adolescents
9. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
10. Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry
11. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
12. Characterisation and outcome of RAC1 mutated melanoma
13. Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease
14. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review
15. Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
16. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
17. Genetic association and differential expression of HLAComplexGroup lncRNAs in pemphigus
18. Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food
19. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
20. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
21. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
22. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
23. Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry
24. Risk Factors and Characteristics of Biphasic Anaphylaxis
25. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
26. 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG
27. Melanoma-Associated Retinopathy
28. Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register
29. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOG
30. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence
31. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma
32. Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
33. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma
34. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
35. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
36. Melanomassoziierte Retinopathie als Prognosefaktor
37. Melanoma-Associated Retinopathy
38. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
39. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
40. Melanoma-Associated Retinopathy
41. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
42. Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma
43. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
44. Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group
45. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case–control study
46. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
47. Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and-DRB1*07:01, in Germans
48. Delayed-Type Heparin Allergy: Diagnostic Procedures and Treatment Alternatives-A Case Series Including 15 Patients
49. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome
50. Einfluss des BRAF‐V600 Mutationsstatus auf die Effizienz einer Immun‐Checkpoint‐Blockade : Eine Auswertung des ADOREG
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.